Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 179-185 , July 2003

Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas

  • Boniface J. Lin

      Affiliations

    • National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Cardinal Tien Hospital, 362 Tsong-Cheng Road, Sintien City, Taipei County 23137, Taiwan
    • ,
  • Huey-Peir Wu

      Affiliations

    • National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • H.S. Huang

      Affiliations

    • Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
    • Deceased.
    • ,
  • Jyuhn Huarng

      Affiliations

    • Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
    • ,
  • A. Sison

      Affiliations

    • Maria Reyna Hospital, Cagayan de Oro, Philippines
    • ,
  • Dato Khalid bin Abdul Kadir

      Affiliations

    • University Kebangsaan Malaysia, Kuala Lumpur, Malaysia
    • ,
  • Chung-Gu Cho

      Affiliations

    • Kwang University Hospital, Cheonbuk, South Korea
    • ,
  • Witaya Sridama

      Affiliations

    • Chualongkorn University Hospital, Bangkok, Thailand
    • ,
  • The Writing Group for the Asian Study of Acarbose with Sulfonylureas

Received 26 November 2001 ,Revised 14 November 2002 ,Accepted 18 November 2002.

References 

  1. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001;24:775–778
  2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine. 1997;14(Suppl. 5):S1–S85
  3. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993;46:1025–1054
  4. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care. 1998;21:1236–1239
  5. Bayraktar M, Van Thiel DH. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care. 1996;19:252–254
  6. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes and Metabolism Research Review. 2000;16:125–132
  7. Chan JCN, Chan K-WA, Ho LLT, Fuh MMC, Hom LC, Sheaves R, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care. 1998;21:1058–1061
  8. Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Research and Clinical Practice. 2000;50:S3–S7 Suppl.
  9. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 1995;18:817–824
  10. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. American Journal of Medicine. 1995;98:443–451
  11. Deerochanawong C, Serirat S, Kornthong P. Efficacy of acarbose as monotherapy in NIDDM patients. Journal of the Medical Association of Thailand. 1996;79:69–75
  12. Duckworth WC. Hyperglycemia and cardiovascular disease. Current Atherosclerosis Reports. 2001;3:383–391
  13. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Reviews. 1998;19:583–592
  14. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Research and Clinical Practice. 2000;50:49–56
  15. Hanefeld M. Post-prandial hyperglycaemia and vascular disease. International Journal of Clinical Practice. 2000;(Suppl. 112):13–18
  16. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. The DIS Group: risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–1583
  17. Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care. 1996;19:642–647
  18. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. The Essen Study. Diabetes Care. 1994;17:561–566
  19. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-II Study. American Journal of Medicine. 1997;103:483–490
  20. Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Research and Clinical Practice. 1998;40:S35–S42 Suppl.
  21. Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2056–2061
  22. Lam KSL, Tiu SC, Tsang MW, Ip TP, Tam SCF. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care. 1998;21:1154–1158
  23. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Research and Clinical Practice. 1998;40:63–70
  24. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Research and Clinical Practice. 2001;52:193–204
  25. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care. 1990;13(Suppl. 3):32–36
  26. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2050–2055
  27. Soonthornpun S, Thamprasit A, Rattarasarn C, Leetanaporn K. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial. Journal of the Medical Association of Thailand. 1998;81:195–200
  28. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000;23:1830–1834
  29. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine. 2001;161:397–404
  30. Turner RC. The UK Prospective Diabetes Study. A review. Diabetes Care. 1998;21(Suppl. 3):C35–C38
  31. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  32. UKPDS Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UKPDS 44). Diabetes Care. 1999;22:960–964
  33. Zaini A. Where is Malaysia in the midst of the Asian epidemic of diabetes mellitus?. Diabetes Research and Clinical Practice. 2000;50:S23–S28 Suppl.

PII: S1056-8727(02)00258-1

doi: 10.1016/S1056-8727(02)00258-1

Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 179-185 , July 2003

Article Tools

* Image Usage & Resolution